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Abstract
Background: In this study, three commercial systems for the preparation of platelet-rich plasma (PRP) were compared and
platelet growth factors release was measured.
Methods: Ten healthy volunteers donated whole blood that was fractionated by a blood cell separator, and a table-top
centrifuge to prepare PRP. Furthermore, an autologous growth factor filter was used to concentrate PRP fractionated by the
blood cell separator. PRP was subsequently activated with autologously produced thrombin to degranulate the platelets to
measure platelet-derived growth factor-AB (PDGF-AB), transforming growth factor-beta (TGF-b), insulin-like growth
factor-1 (IGF-1), and vascular endothelial growth factor (VEGF).
Results: PRP contained significantly higher platelet counts compared with baseline values ( p , 0.001). PDGF-AB
concentrations were increased more than 18-fold in the platelet gel supernatant when the cell-separator and GPS were used,
whereas only a 3-fold increase was seen with the AGF.
Conclusion: The three PRP devices enable the preparation of PRP for the release of high concentrations of platelet growth
factor, but showed different harvesting capacities for the collection of concentrated platelets. The administration of thrombin
for PRP activation resulted in the release of high concentrations of PDGF-AB and TGF-b but only when PRP had not been
activated during the preparation process in vitro.
Keywords: Platelet gel, platelet growth factor, platelet-rich plasma, platelet activation
Introduction
Traditionally, platelets are used therapeutically to
correct thrombocytopenia or platelet dysfunction
(Sensebe et al. 2005). It is currently understood that
platelets also play a pivotal role in the repair of injured
tissues since they contain platelet growth factors that is
released from activated platelets; platelet growth
factors initiate and modulate wound healing in bone
or soft tissue (Bourquie et al. 1993, Mazzuco et al.
2004). Of particular importance in these healing
processes is platelet-derived growth factor (PDGF),
which exists as both heterodimers of A and B chains
and as homodimers of either A–A or B–B chains
(Pierce et al.1991). Also of importance are transform-
ing growth factor-beta (TGF-b) (Rosier et al.1998),
vascular endothelial growth factor (VEGF) (Rhee et al.
2004), smaller amounts of insulin-like growth factor
(IGF) (Weibrich et al. 2002a) and epidermal growth
factor (EGF) (Martin et al. 1992). Additionally,
Kubota and others described that connective tissue
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growth factor (CTGF) is also present (Kubota et al.
2004). Recently, strategies in clinical treatment plans
encourage the production of autologous platelet-rich
plasma (PRP) containing high concentrations of
platelet growth factors with the use of whole blood
separation devices. PRP mixed with thrombin and
calcium chloride will result in the production of
platelet gel, which can be exogenously applied to
surgical wounds, leading to the degranulation of the
platelet a granules and platelet growth factor release
(Fre´chette et al. 2005). In several studies, investigators
have appeared to take advantage of platelet growth
factor delivery in support of hemostasis and wound
healing (Englert et al. 2005, Everts et al. 2006). In oral
and maxillofacial surgery, published results imply that
earlier bone graft maturation can be expected when
platelet gel is used in mandibular defects (Marx et al.
1998, Steigmann and Garg 2005). In addition,
platelet gel applications have also been reported to
improve soft tissue healing in chronic non-healing
wounds (Margolis et al. 2001, Crovetti et al. 2004).
Before clinicians began to routinely use platelet gel, it
was logical to analyze the manufacturing procedure
for PRP, which may result in varying amounts, quality,
and efficacy from patient to patient, and to
characterize the platelet growth factor content. The
purpose of this study was to evaluate the PRP
preparation method in 10 healthy volunteers and
compare the results obtained using three different
commercially available devices with different operat-
ing principles. The specific objectives were: 1. To
compare platelet counts, 2. To determine whether
platelet activation occurs during the PRP preparation
process, 3. To examine the effects of PRP storage on
growth factor levels, and 4. To quantitate certain
platelet growth factors (i.e., PDGF, TGF-b, VEGF,
and IGF) in the platelet gel.
Material and methods
Study design
The study was approved by the Institutional Ethics
Committee of the Catharina Hospital (Eindhoven,
The Netherlands) (World Medical Association 2002).
Written, informed consent was obtained according to
the guidelines. Each volunteer was identified by
number, enabling a reviewer to identify and compare
the test results. The study was consecutively executed
in five working days.
Materials
The Gravitational Platelet Sequestration Systeme,
(Biomet Co, Warsaw, IN, USA) (GPS), is a table-top
centrifuge system using a flat-bottom, 60-ml plastic
centrifuge tube, containing a buoy and an internal
coiled device located in the tube cap. The buoy is
lowered to remove the platelet-poor plasma following
a 12 min spin at 3200 rpm. Thereafter, the PRP
volume (^5 ml) can be collected. With this device, the
red blood cells cannot be collected separately and are
therefore discarded.
The Electa Cell-Separatore (Sorin Group,
Mirandola, Italy) (CS) is an intraoperative blood
salvage device that uses a Latham bowl to separate the
PRP from the whole blood and utilizes modified
software for apheresis (11). One PRP production
procedure incorporates both a 5400-rpm hard spin
and a 2400-rpm soft spin to collect the PRP. The
platelet poor plasma and erythrocytes are collected
separately in two transfusion bags and retransfused to
the patient. The PRP is collected in a 60-ml syringe.
The Autologous Growth Factor Filtere, (Interpore
Crossw, Irvine CA, USA) (AGF) is a microporous,
hollow, cellulose fiber filtration device with a volume
of 8 ml and uses PRP as a baseline product that has
been manufactured by the cell separator device. A
specific manifold is needed for the AGF, which has
two 60-ml syringes attached that are driven by
compressed air. The device filters water after multiple
passes of PRP through the filtration device. The end-
product is concentrated PRP. All three devices were
used according to the manufacturer’s instructions.
Methods
PRP preparation
An intravenous infusion line was inserted into the
medial cubital vein using a 17-g needle. For each
donor, whole blood donation was distributed as 2
aliquots. First, a 60-ml syringe was pre-filled with 7 ml
of anticoagulant citrate dextrose A solution and 53 ml
of whole blood was slowly drawn via an intravenous
catheter. The syringe was inverted five times to ensure
proper mixing with the anti-coagulant before PRP was
prepared using the GPS. An additional 375 ml of
blood was passively drained into a blood bag contain-
ing 53 ml of citrate–phosphate–adenine anticoagu-
lant-preservative to produce PRP using the CS, which
was programmed to perform platelet sequestration.
The PRP from the CS was divided into 3 aliquots:
4 ml for the preparation of autologous thrombin, 3 ml
was kept for platelet gel fractionation, and the
remainder was used for the concentration of PRP
using AGF. The PRP prepared using the GPS was
solely used to produce platelet gel.
Platelet gel enrichment
Following PRP preparation, autologous thrombin was
isolated to activate the PRP and thus to prepare
platelet gel. Autologous thrombin was isolated from
4 ml PRP and 0.17 ml of 10% calcium chloride to
antagonize the anticoagulant present in the donated
P. A. M. Everts et al.166
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blood. This mixture was injected into a glass Petri dish
to activate platelets and form a clot. After 25 to
40 min, a clot was formed inside the glass dish and
compressed manually. The cellular clot debris was left
behind on the dish and the liquid fraction containing
the thrombin was aspirated with a syringe. Platelet gel
was prepared by mixing PRP and thrombin in a ratio
of 4:1. Figure 1 shows a diagram on the study set-up.
Sampling and hematological analysis
Blood samples used for baseline measurements were
drawn from the intravenous line of the patient and
collected in citrate–phosphate–adenine monovettes.
After whole blood centrifugation procedures using the
three devices, a sample of the PRP volume was taken for
laboratory analysis. Subsequently, the PRP of the GPS
and 3 ml of the CS were placed onto a flatbed agitator at
a frequency of 60 rpm and stored at room temperature
(21 ^ 28C) for 75 min during PRP was concentrated
using the AGF. After this period, blood samples were
taken from the PRP and concentrated PRP. Then, 3 ml
of PRP from the GPS, CS, and concentrated PRP were
activated by autologous thrombin to form the viscous
coagulum, platelet gel. The platelet gel coagula were
placed into three different cups that represented each
device; after 75 min, a sample was taken from each
supernatant for analysis.
In all blood samples, platelet counts were assessed
using a fully automated analyzer (Cell-Dyne 4000,
Abbott Diagnostics, Santa Clara, CA, USA) and the
impedance method.
Determination of platelet activation
During the entire PRP and platelet gel preparation
procedures, platelet activation was determined by
measuring plasma levels of beta-thromboglobulin
using Asserachrome beta-thromboglobulin kits
(Stago, Asnieres, France).
Determination of growth factor concentrations
Platelet growth factor concentrations in whole blood,
PRP, concentrated PRP, and platelet gel supernatants
were determined by commercially available enzyme-
linked immunosorbent assay kits (R&D Systems,
Minneapolis MN, USA) that had been validated for
measuring PDGF-AB (Quantikine PDGF-AB),
TGF-b1 (Quantikine TFG-b1), and VEGF (Quanti-
kine human ANG), according to the manufacturer’s
instructions. The enzyme-linked immunosorbent
assay procedures were programmed into an auto-
mated analyzer (Coda Automated EIAe analyser;
Bio-Rad Laboratories, Hercules CA, USA). Samples
were measured in duplicate and in appropriate
dilutions to fit the respective calibration curves.
Repeat analysis was performed when between
duplicate differences greater than 10% were found.
Insulin-like growth factor-1 (IGF-1) was measured
using a fully automated chemiluminescence immuno-
assay in the Advantage Analyzer (Nichols Institute
Diagnostics, San Clemente CA, USA).
Statistical method
The study data were gathered on customized patient
tracking forms and entered into a computerized
database that allowed unbiased and reliable data
management. Statistical analysis utilized SAS statis-
tical software (SAS Institute, Cary, NC; USA, 2003).
Measured data were expressed as the mean ^ 1
standard deviation (SD). The measurements of
interest were the changes within each individual
from one time point to the next and the average. The
paired t-test focused on the difference between the
paired data and reported the probability that the
actual mean difference was equal to zero. Differences
were calculated for all measurements from Time 1 to
Time 0, Time 2 to Time 0, and Time 3 to Time 0 for
each individual. These differences were averaged for
the specific device type. T-tests for significant
differences between devices were then calculated,
where p , 0.05 was considered significant (Time
0 ¼ baseline, Time 1 ¼ after PRP preparation, Time
3 ¼ after 75 min, and Time 4 ¼ after activation by
autologous thrombin).
The platelet yield, a measurement to validate the
collection efficiency of the devices, was determined
using the following formula:
VOLUNTEER
 
PPP RBC PRP
discard
I.V.- line
7 mL ACDA 
53 mL WB 
53 mL CPDA 
325 mL WB 
GPS CS
AT Prep
PG PG
AGF
cPRP
PG 
PRP RBC PPP
discard
Figure 1. I.V-line: intra venous line; ACDA: anticoagulant citrate
dextrose A CPDA: citrate–phosphate–adenine anticoagulant-
preservative; WB: whole blood; GPS: GPS table top; CS: Electa
cell-saver; PPP: platelet-poor plasma; PRP: platelet-rich plasma;
RBC: red blood cells; AT Prep: autologous thrombin preparation;
AGF: autologous growth factor filter; cPRP: concentrated platelet-
rich plasma; PG: platelet gel.
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Platelet yield (%) ¼ (PRP volume) £ (platelet
count in PRP)/(WB volume) £ (platelet in
WB)*100%. (WB: whole blood).
Results
Preparation of platelets
Blood samples were collected from 10 healthy
volunteers (5 men, 5 women), aged 24 to 54 years
(38 ^ 9 years, mean ^ SD), who were not taking any
medications. All donors in this study had a platelet
count greater than 150,000/ml, and the mean
hematocrit was 42 ^ 4% (SD). In Table I, the
characteristics of the PRP preparation for the three
devices are compared. With each device, we found
that platelet numbers significantly increased com-
pared with the baseline donor platelet count for the
CS, GPS ( p , 0.001), and AGF ( p , 0.05). After
comparing the mean PRP platelet counts, it was noted
that PRP prepared using the CS contained signi-
ficantly more platelets ( p , 0.001) than preparations
using the other two devices. Furthermore, the CS
resulted in a significantly higher platelet yield than
those obtained using the GPS and AGF: 47%, 36%,
and 32%, respectively. The relative increase in platelet
count above baseline platelet count in the whole blood
sample was the lowest for the AGF, despite the fact
that the PRP volume was reduced 2.5-fold with
the AGF.
Platelet activation during PRP preparation
Activated platelets were shown to release beta-
thromboglobulin; these results are shown in Table II.
The beta-thromboglobulin levels for both the CS and
GPS were not statistically different following PRP
preparation. After PRP activation by autologous
thrombin, release was 10-fold higher than in non-
activated PRP ( p , 0.001 for both systems). PRP
storage had no significant effect on platelet activation.
In contrast with the CS and GPS, we noted a
significantly higher beta-thromboglobulin concen-
tration after filtration procedure in the concentrated
PRP ( p , 0.001) using the AGF. When the concen-
trated PRP was activated by thrombin, only a minor
release could be measured, indicating less residual
platelet activation.
Growth factor release into the PRP supernatant
In Table III, the IGF-1 and VEGF data are shown.
Low levels of IGF-1 were detected in the supernatants
from non-activated PRP and did not significantly
increase after the addition of thrombin with any of the
three devices. Mean VEGF concentrations were
detectable in the PRP of the CS and GPS (204 ^ 53
and 191 ^ 36 ng/ml, respectively) and in the concen-
trated PRP of the AGF (250 ^ 80 ng/ml).
The results in Table IV 1 reflect the PDGF-AB and
TGF-b1 levels after PRP, concentrated PRP prep-
aration, and subsequent platelet gel production.
Compared to the CS and GPS, we observed
significantly increased levels of both PDGF-AB and
TGF-b immediately after concentrated PRP prep-
aration using AGF ( p , 0.001). After activation by
thrombin, the PRP of the CS and GPS resulted in a
significant increase in growth factor release
( p , 0.001) when compared with the AGF.
The largest increase was observed by the release of
Table I. Characteristics of PRP production§.
System WB PLT concentration ( £ 103/ml) PRP PLT ( £ 103/ml) PLT increase baseline PLT yield (%)
CS 219 ^ 81 1051 ^ 276* 4.9 ^ 0.7 48 ^ 12*
GPS 219 ^ 81 569 ^ 247* 2.8 ^ 1.1 36 ^ 15
AGF 1051 ^ 276 1222 ^ 326† 1.2 ^ 0.1 32 ^ 11
§All values represent the mean ^ SD (PRP: platelet-rich plasma).
Platelet increase Baseline is a value representing the increase in PRP platelet count compared to the baseline platelet count. PLT: platelet.
* p , 0.001,
† p , 0.05. WB: whole blood.
Table II. b-TG activation (IU/ml) during PRP separation§.
System
PRP
After 75 min
Non-activated Thrombin-activated storage PRP
CS 1666 ^ 1058 24,207 ^ 13,117* 2420 ^ 1443
GPS 1741 ^ 1417 23,130 ^ 10,820* 2164 ^ 1407
AGF† 26,574 ^ 10,185* 38,629 ^ 14,732 N/A
§All values represent the mean ^ SD.
cPRP: concentrated platelet-rich plasma; PRP: platelet-rich plasma, N/A: not applicable.
* AGF product is concentrated PRP, † p , 0.001.
P. A. M. Everts et al.168
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PDGF-AB (more than 18-fold compared with the
PRP levels).
Discussion
In this study, we observed that the PRP devices
particularly differ in their abilities to collect concen-
trated and non-activated platelets from whole blood
for the enrichment of PRP. High concentrations of
PDGF-AB and TGF-b were released after PRP
activation by autologous thrombin.
Under normal circumstances, wound healing is
initiated through platelet activation and aggregation in
the presence of calcium and thrombin, generating a
fibrin clot in which a matrix for migration of tissue-
forming cells will be formed (Lin et al. 1997). During
the wound-healing cascade, platelets are trapped and
activated, resulting in the release of growth factors
present in the a-granules of the platelets (Slater et al.
1995). The effects of autologous concentrated platelet
growth factors, delivered as a platelet gel, have been
studied to some extent during various surgical
procedures (Marx et al. 1998, Margolis et al. 2001,
Crovetti et al. 2004, Englert et al. 2005, Steigmann
and Garg 2005, Everts et al. 2006). At present, no
standardized protocols for peri-operative harvesting of
PRP and subsequent platelet gel application have been
formulated, although the number of PRP-producing
devices is increasing. The currently available PRP
processing devices have rarely been validated with
ample information for the clinician concerning the
quality of the manufactured PRP and the growth
factor content of the platelet gel (Kevy and Jacobson
2004, Weibrich et al. 2005). Zimmerman and co-
workers discussed this lack of standardized protocols.
They applied standard blood bank criteria to
investigate different methods for the preparation of
platelets and identified factors that influence the
production of platelet gel (Zimmerman et al. 2001). It
was our objective to compare platelet collection
efficiency, monitor platelet activation during PRP
preparation, and observe platelet growth factor release
after PRP activation using three different commercial
point-of-care devices. The technical design and
operating principles of the devices that produce PRP
are completely different, but are all presently being
used in clinical settings. The use of the CS demands
larger whole blood volumes to prepare PRP. We
routinely use this device either in combination with
red cell salvage techniques, or when larger platelet gel
volumes are therapeutically indicated. The advantage
of this device is that the disposable kit can be used
repetitively to sequester whole blood. Furthermore, all
produced blood components are retransfused to the
patient using aseptic techniques to avoid contami-
nation. The GPS is a low-volume device and prepares
therefore small PRP volumes. The disposable set can
be used once. Due to the construction of the GPS
blood separation chamber, the manufacturer
recommends sterile gloves be worn during the PRP
collection steps, which is performed manually. The
AGF is a modified hemoconcentrator that requires
PRP be prepared using a cell salvage device for further
PRP concentration. Nevertheless, in some papers, the
Table III. IGF and VEGF concentrations after PRP separation and thrombin activation§.
IGF-1 PRP (mg/l) VEGF PRP (ng/l)
System Non-activated Thrombin-activated Non-activated Thrombin-activated
CS 100 ^ 29 87 ^ 34 204 ^ 53 144 ^ 49
GPS 99 ^ 29 107 ^ 29 191 ^ 36 191 ^ 37
AGF* 132 ^ 32 102 ^ 35 250 ^ 80 219 ^ 58
§All values represent the mean ^ SD.
PRP: platelet-rich plasma.
* AGF product is concentrated PRP.
Table IV. PDGF-AB and TGF-b1 values after PRP separation and thrombin activation§.
PDGF-AB (pg) TGF-b1 (pg)
System Non-activated Thrombin activated Non-activated Thrombin-activated
CS 8982 ^ 1899 145,995 ^ 61,259* 2501 ^ 899 8798 ^ 2301*
GPS 4194 ^ 1009 109,908 ^ 48,885* 1379 ^ 785 4102 ^ 1734‡
AGF† 151,766 ^ 47,989* 119,747 ^ 48,723 5389 ^ 1452* 3285 ^ 1288
§All values represent the mean.
PRP: platelet-rich plasma. PG: platelet gel.
* AGF product is concentrated PRP.
‡ p , 0.001,† p , 0.05.
Platelet-rich plasma preparation 169
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effect of applying concentrated PRP to tissues to
increase growth factor delivery revealed no effect
(Lowery et al. 1999, Weiner and Walker 2003, Castro
2004, Carreon et al. 2005). To account for the device
differences in preparation volume, and therefore PRP
volume, we calculated the total amount of growth
factors rather than measuring the individual concen-
trations of PDGF-AB and TGF-b.
The results of our investigation are to some extent in
accordance with the data of Kevy and Jacobson (Kevy
and Jacobson 2004). We showed that the overall
platelet collection efficiency and platelet count of the
PRP were dissimilar for the three devices. The cell-
salvage device significantly showed the highest platelet
recovery (platelet yield of 48%) and the highest
platelet count in the PRP than the other two devices.
The lowest platelet yield was measured in the AGF
device. Despite the fact that the actual PRP volume of
the AGF system was decreased by a factor of 2.8, we
did not observe an equal rise in platelet counts, which
means that platelets were lost during the concen-
tration process. Weibrich et al. performed similar
studies using the PCCSe system and the Anitua
Platelet-Rich-in-Growth Factor Kit (Weibrich et al.
2005). They also demonstrated significantly different
platelet collection efficiencies and platelet counts,
supporting our impression that there might be a large
variation among devices for the harvest of PRP.
In our study, we observed that the different platelet
harvesting methods had a significant effect on the
activation of PRP and platelet growth factor release
from the platelet gel. Therefore, it is critical to validate
and understand the PRP preparation process before
platelet gel techniques are applied to patients. To
evaluate the quality of the PRP preparation process,
we monitored platelet activation. An established in vivo
method to measure platelet activation is the detection
of b-TG as a marker of platelet activation. The AGF
system showed the highest b-TG release after PRP
processing. In our opinion, this finding might be the
result of the repetitive passes of the platelets through
the microporous fibers of the hemoconcentrator. The
platelets adhere to the surface of the hollow fibers, a
phenomenon that is well described with the use of
these devices during dialysis (deSa et al. 2001). This is
the most likely reason why the increase in platelet
count of the concentrated PRP was not in accordance
with our expected 2.8-fold increase in platelet count.
In contrast to this finding, we noticed that PRP
obtained with the other two systems demonstrated
minimal platelet activation, even after a 75-min
storage period. When PRP was activated by thrombin,
platelet gel was formed and platelets were immediately
activated as measured by beta-thromboglobulin levels
that increased 12.3- and 13.5-fold compared with the
PRP levels for the GPS and CS devices, respectively.
The concentrated PRP of the AGF showed only a
3.2-fold increase in platelet activation, indicating that
the vast majority of platelets in the concentrated PRP
had been activated before platelet gel was prepared.
During clinical platelet gel applications, concen-
trated and activated platelets are exogenously applied
to wound sites where they adhere to tissues and start to
degranulate, resulting in the release of platelet growth
factors. Slater et al. and Spencer and co-workers have
demonstrated that platelet growth factors have
mitogenic and chemotactic properties that may
contribute to improved wound healing (Spencer et al.
1993, Slater et al. 1995). Therefore, it is important
that platelet gel applied in vivo can deliver viable
growth factors. This ability decreases when PRP
becomes activated in vitro before platelet gel is
delivered to tissues. For this reason, we measured
platelet growth factor concentrations after the
preparation of PRP and concentrated PRP, and after
activation by autologous thrombin. Compared to the
levels of growth factors found with the use of the CS
and GPS systems, we observed a significant increase
in PDGF-AB and TGF-b concentrations in the
concentrated PRP samples, strongly suggesting pre-
mature growth factor release prior to thrombin
activation with the concentrated PRP method. There-
fore, less PDGF-AB and TGF-b was measured in the
platelet gel supernatant when compared to the other
two devices. The AGF end product is therefore not a
viable platelet concentrate but rather a platelet
releasate. After activation by autologous thrombin, a
significant increase in PDGF-AB and TGF-b levels
was measured in the platelet gel supernatants of both
systems, whereas the platelet gel in accordance with
the results of our b-TG measurements, indicated
massive platelet activation following the use of the
AGF system and only a minor response to autologous
thrombin activation. As demonstrated by Weibrich
et al, the IGF-1 concentrations in PRP as well as in
platelet gel were not statistically different and
remained very low (Weibrich et al. 2002b). An
explanation for this observation might be that IGF-1
released from platelets is very low since the plasma
pool of IGF-1 is greater than the platelet pool (Karey
et al. 1989) and that IGF-1 is primarily excreted by the
liver into the plasma (Rubin and Baserga 1995. The
mean VEGF values after activation by thrombin were
almost similar in PRP and concentrated PRP levels,
suggesting that activation by autologous thrombin and
calcium does not significantly increase VEGF release
during the incubation period.
In conclusion, we studied three different methods to
obtain PRP for the in vitro production of platelet gel.
Our findings indicate that PRP can be sequestered and
concentrated 5-fold from one unit of whole blood.
Moreover, a comparison of the devices demonstrated
discrepancies in both quality of the PRP preparation
method and quantity of platelet growth factors
released after thrombin activation. With the CS and
GPS systems, we could reproduce consistent data
P. A. M. Everts et al.170
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regarding growth factor release, specifically for
PDGF-AB and TGF-b. However, the AGF system
appeared to generate concentrated, but activated,
platelets that released growth factors prior to the
preparation of platelet gel. Although our study was not
directed toward measuring biological effects of
platelet gel, it is likely that the clinical effectiveness
of platelet gel prepared with the AGF device is lower
than those of the two other systems. Acceptance of
standardized protocols for PRP enrichment and
subsequent platelet gel application should be insti-
tuted in order to achieve and maintain a high quality
biological product. Further research is mandatory to
assess the healing applications of platelet gel and to
determine its effects in a variety of medical disciplines.
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